Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 Patralekha Chatterjee NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue. Continue reading -> Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 Guest contributor The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen 't Hoen. Continue reading -> Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Brexit Drives European Medicines Agency To The Netherlands, Move By March 2019 21/11/2017 Catherine Saez As a consequence of the decision of the United Kingdom to go its separate way, the remaining European Union member states decided yesterday that the European Medicines Agency should move to Amsterdam by the end of March 2019. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Hepatitis C Buyers’ Clubs Grow Worldwide As A Way To Obtain Affordable Treatment 07/11/2017 Tatum Anderson Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million worldwide and kills around 400,000 people a year. But importantly, these groups of patients from Russia to Australia have got together to help each other import a relatively new class of drug that is able to cure most of the patients who take it. Continue reading -> Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 Catherine Saez A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. Continue reading -> Posts navigation Older postsNewer posts